Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).

@article{Chan2003TripleAT,
  title={Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).},
  author={Albert W K Chan and David J Moliterno and Peter B. Berger and Gregg Whitney Stone and Peter M Dibattiste and Steven L Yakubov and Shelly K Sapp and Kathy E Wolski and Deepak L Bhatt and Eric J. Topol},
  journal={Journal of the American College of Cardiology},
  year={2003},
  volume={42 7},
  pages={1188-95}
}
OBJECTIVE We sought to examine if clopidogrel treatment initiated before coronary stenting improved clinical outcomes among patients receiving aspirin and a glycoprotein (GP) IIb/IIIa inhibitor. BACKGROUND Antiplatelet therapy plays a pivotal role in contemporary percutaneous coronary interventions (PCI). METHODS Outcomes among 4,809 patients randomized to tirofiban or abciximab during PCI with stent placement were compared according to whether they received 300 mg of clopidogrel before PCI… CONTINUE READING
36 Citations
51 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Similar Papers

Loading similar papers…